Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. Its rare disease portfolio comprises TNX-2900 for the treatment of Prader-Willi syndrome. The company's infectious disease pipeline includes TNX-801, a vaccine to prevent smallpox and monkeypox; TNX-1840 and TNX-1850 that are live virus vaccines based on its recombinant pox vaccine (RPV) platform for COVID-19; TNX-3500, a small molecule antiviral drug to treat acute COVID-19; and TNX-102 SL, a small molecule drug to treat Long COVID, a chronic post-acute COVID-19 condition. Its CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions, including TNX-102 SL, which is in mid-Phase 3 development for the management of fibromyalgia; TNX-1900 that is in development for the prevention of migraine headache; and TNX-1300, a biologic designed to treat cocaine intoxication. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

Tonix Pharmaceuticals Holding Corp.

Neuro Vigor Therapeutics is a development stage company focused on reducing reactive aldehyde species, which are significant contributors to multiple diseases, trauma, and pain.

Neuro Vigor Therapeutics

Tonix Pharmaceuticals focuses on the development of innovative treatments in areas such as the central nervous system, immunology, infectious diseases, and rare diseases. The company is involved in advancing scientific programs and has a pipeline of investigational new drugs and biologics, including FDA-approved products for acute migraine.

Metric
Company Name	Tonix Pharmaceuticals Holding Corp.	Neuro Vigor Therapeutics
Symbol	TNXP
MSH ID	COM:TONIXPHARMA	COM:NVTHERAPEUTICS
Market	STOCKS	PRIVATE
Sector	Healthcare	Healthcare & Health Services
Industry	Biotechnology	Biotechnology
Country	US	US
Stage
Employee Count	103
Website	tonixpharma.com	nvtherapeutics.com
LinkedIn
Founders

Metric
Market Cap	6.10M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	7.77M
Revenue (LTM)
Revenue (NTM)
Gross Profit	3.03M
EBITDA	-118.38M
Operating Income	-118.38M
Net Income	-116.66M
EPS	-0.01
Diluted EPS	-0.01
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.13
Operating Profit Margin	-2.84
EBITDA Margin	-15.24
Net Profit Margin	-2.76
Return on Equity	-0.79
Return on Assets	-0.73
Return on Capital Employed	-0.87

COM:TONIXPHARMA

Tonix Pharmaceuticals

Last Close

0.20

22/11 21:00

Market Cap

6.10M

Beta: -

Volume Today

1.92M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-0.04
P/B Ratio	0.04
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	1.98
EV Multiple	0.03

Metric
Days Sales Outstanding	15.05
Days Payables Outstanding	90.73
Days Inventory Outstanding	276.94
Operating Cycle	374.77
Cash Conversion Cycle	144.93
Asset Turnover	0.27

Metric
Operating Cash Flow	-102.00M
Free Cash Flow	-109.90M
Cash Flow to Debt	-8.23
Operating Cash Flow/Sales	-2.43
Free Cash Flow Yield	-4.38

Metric
Cash & Equivalents
Accounts Receivable
Inventory	508K
Goodwill
Debt to Capitalization	0.17
Debt to Assets	0.01
Current Ratio	1.77
Quick Ratio	1.56

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.26
R&D to Revenue	2.49
SG&A to Revenue	0.59